Chronic Lymphocytic Leukemia - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Chronic Lymphocytic Leukemia > What Your Doctor is Reading About Chronic Lymphocytic Leukemia > Review Articles

Review Articles

1. Novel immune-based treatment strategies for chronic lymphocytic leukemia.

Author: Wierda WG; Kipps TJ; Keating MJ;
Institution: The University of Texas M.D. Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA. wwierda@mdanderson.org
Journal: J Clin Oncol. 2005 Sep 10;23(26):6325-32.
Abstract URL: Click here to view abstract

2. Chronic lymphocytic leukemia: economic burden and quality of life: literature review.

Author: Stephens JM; Gramegna P; Laskin B; Botteman MF; Pashos CL;
Institution: HERQuLES, Bethesda, Maryland, USA.
Journal: Am J Ther. 2005 Sep-Oct;12(5):460-6.
Abstract URL: Click here to view abstract

3. Monoclonal antibody therapy of chronic lymphocytic leukemia.

Author: Cheson BD;
Institution: Lombardi Comprehensive Cancer Center, Georgetown University Hospital, 3800 Reservoir Rd, NW, Washington, DC, USA. bdc4@georgetown.edu
Journal: Cancer Immunol Immunother. 2006 Feb;55(2):188-96. Epub 2005 Sep 27.
Abstract URL: Click here to view abstract

4. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?

Author: Bruserud O; Tronstad KJ; McCormack E; Gjertsen BT;
Institution: Section for Hematology, Institute of Medicine, The University of Bergen, Bergen, Norway. oystein.bruserud@haukeland.no
Journal: Cancer Immunol Immunother. 2006 Feb;55(2):221-8. Epub 2005 Jul 21.
Abstract URL: Click here to view abstract

5. Immunotherapy in chronic lymphocytic leukemia.

Author: Bruserud O; McCormack E; Gjertsen BT;
Institution: Section for Hematology, Institute of Medicine, The University of Bergen, Bergen, Norway. oystein.bruserud@haukeland.no
Journal: Cancer Immunol Immunother. 2006 Feb;55(2):185-7. Epub 2005 Jul 7.

6. The evolving role of lenalidomide in the treatment of hematologic malignancies.

Author: Kastritis E; Dimopoulos MA; Kastritis E; Dimopoulos MA;
Institution: Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, School of Medicine, Athens, Greece.
Journal: Expert Opin Pharmacother. 2007 Mar;8(4):497-509.
Abstract URL: Click here to view abstract

7. Dendritic cell vaccines for leukemia patients.

Author: Schmitt A; Hus I; Schmitt M; Schmitt A; Hus I; Schmitt M;
Institution: Tumor Immunology Group, University of Ulm, Clinic for Internal Medicine III, Robert-Koch-Str. 8, 89081 Ulm, Germany. anita.schmitt@uni-ulm.de
Journal: Expert Rev Anticancer Ther. 2007 Mar;7(3):275-83.
Abstract URL: Click here to view abstract

8. Flavopiridol in the treatment of chronic lymphocytic leukemia.

Author: Christian BA; Grever MR; Byrd JC; Lin TS;
Institution: Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA.
Journal: Curr Opin Oncol. 2007 Nov;19(6):573-8.
Abstract URL: Click here to view abstract

9. Recent progress in the management of chronic lymphocytic leukemia.

Author: Robak T;
Institution: Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland. robaktad@csk.umed.lodz.pl
Journal: Cancer Treat Rev. 2007 Dec;33(8):710-28. Epub 2007 Sep 27.
Abstract URL: Click here to view abstract

10. Cellular immune therapy for chronic lymphocytic leukemia.

Author: Kater AP; van Oers MH; Kipps TJ;
Institution: Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands. a.p.kater@amc.uva.nl
Journal: Blood. 2007 Oct 15;110(8):2811-8. Epub 2007 Jul 16.
Abstract URL: Click here to view abstract

11. Controversies in the front-line management of chronic lymphocytic leukemia.

Author: Nabhan C; Shanafelt TD; Kay NE;
Institution: Oncology Specialists, S. C., Lutheran General Hospital, Department of Medicine, Division of Hematology and Medical Oncology, Park Ridge, IL 60068, USA. cnabhan@oncmed.net
Journal: Leuk Res. 2008 May;32(5):679-88. Epub 2008 Jan 11.
Abstract URL: Click here to view abstract

12. Chronic lymphocytic leukaemia.

Author: Dighiero G; Hamblin TJ;
Institution: Institut Pasteur de Montevideo, Montevideo, Uruguay.
Journal: Lancet. 2008 Mar 22;371(9617):1017-29.
Abstract URL: Click here to view abstract

13. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.

Author: Boyd K; Dearden CE;
Institution: The Royal Marsden Hospital and Institute of Cancer Research, London, UK. kboyd@doctors.org.uk
Journal: Expert Rev Anticancer Ther. 2008 Apr;8(4):525-33.
Abstract URL: Click here to view abstract

14. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.

Author: Kay NE; O'Brien SM; Pettitt AR; Stilgenbauer S;
Institution: Division of Hematology, Mayo Clinic, Rochester, MN, USA. kay.neil@mayo.edu
Journal: Leukemia. 2007 Sep;21(9):1885-91. Epub 2007 Jun 14.
Abstract URL: Click here to view abstract

15. Chronic lymphocytic leukemia.

Author: Ghia P; Ferreri AM; Galigaris-Cappio F;
Institution: Department of Oncology, Universita' Vita-Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy. ghia.paolo@hsr.it
Journal: Crit Rev Oncol Hematol. 2007 Dec;64(3):234-46. Epub 2007 Jun 1.
Abstract URL: Click here to view abstract

16. Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice.

Author: Dasanu CA;
Institution: Seattle Hematology-Oncology, 2202 70th Ave West, University Place, WA 98466, USA. c_dasanu@yahoo.com
Journal: Expert Opin Pharmacother. 2008 Jun;9(9):1481-94.
Abstract URL: Click here to view abstract

17. Lenalidomide for the treatment of B-cell malignancies.

Author: Chanan-Khan AA; Cheson BD; Chanan-Khan AA; Cheson BD;
Institution: Roswell Park Cancer Institute, Buffalo, NY, USA. asher.chanan-khan@roswellpark.org
Journal: J Clin Oncol. 2008 Mar 20;26(9):1544-52. Epub 2008 Feb 19.
Abstract URL: Click here to view abstract

18. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.

Author: Robak T;
Institution: Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93-510 Lodz, ul. Ciolkowskiego 2, Poland. robaktad@csk.umed.lodz.pl
Journal: Curr Cancer Drug Targets. 2008 Mar;8(2):156-71.
Abstract URL: Click here to view abstract

19. Chronic lymphocytic leukemia: diagnosis and treatment.

Author: Yee KW; O'Brien SM;
Institution: Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Mayo Clin Proc. 2006 Aug;81(8):1105-29.
Abstract URL: Click here to view abstract

20. Fludarabine in chronic lymphocytic leukaemia.

Author: Elter T; Hallek M; Engert A;
Institution: First Department of Internal Medicine, University of Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany. thomas.elter@uk-koeln.de
Journal: Expert Opin Pharmacother. 2006 Aug;7(12):1641-51.
Abstract URL: Click here to view abstract

21. Role of allogeneic transplantation in low-grade lymphoma and chronic lymphocytic leukemia.

Author: Thomson KJ; Mackinnon S;
Institution: Royal Free and University College Medical School, London, UK. kirsty.thomson@uclh.org
Journal: Curr Opin Hematol. 2006 Jul;13(4):273-9.
Abstract URL: Click here to view abstract

22. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia.

Author: Gowda A; Byrd JC;
Institution: Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio 43210, USA.
Journal: Curr Opin Hematol. 2006 Jul;13(4):266-72.
Abstract URL: Click here to view abstract

23. Immunomodulating drugs for chronic lymphocytic leukaemia.

Author: Chanan-Khan A; Porter CW;
Institution: Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. asher.chanan-khan@roswellpark.org
Journal: Lancet Oncol. 2006 Jun;7(6):480-8.
Abstract URL: Click here to view abstract

24. Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia.

Author: Winkler D; Dohner H; Stilgenbauer S;
Institution: Department of Internal Medicine III, University of Ulm, Germany.
Journal: Curr Drug Targets. 2006 Oct;7(10):1313-27.
Abstract URL: Click here to view abstract

25. Update on risk-stratified management for chronic lymphocytic leukemia.

Author: Zent CS; Call TG; Hogan WJ; Shanafelt TD; Kay NE;
Institution: Division of Hematology, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA. zent.clive@mayo.edu
Journal: Leuk Lymphoma. 2006 Sep;47(9):1738-46.
Abstract URL: Click here to view abstract

26. Monoclonal antibodies in chronic lymphocytic leukemia.

Author: Ferrajoli A; Faderl S; Keating MJ;
Institution: University of Texas MD Anderson Cancer Center, Department of Leukemia, Unit 428, PO Box 301402, Houston, TX 77230-1402, USA. aferrajo@mdanderson.org
Journal: Expert Rev Anticancer Ther. 2006 Sep;6(9):1231-8.
Abstract URL: Click here to view abstract

27. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.

Author: Shanafelt TD; Byrd JC; Call TG; Zent CS; Kay NE;
Institution: Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Journal: Ann Intern Med. 2006 Sep 19;145(6):435-47.
Abstract URL: Click here to view abstract

28. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.

Author: O'Brien SM; Keating MJ; Mocarski ES;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston , TX 77030, USA. sobrien@mdanderson.org
Journal: Clin Lymphoma Myeloma. 2006 Sep;7(2):125-30.
Abstract URL: Click here to view abstract

29. The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia.

Author: Banerji V; Johnston JB; Seftel MD;
Institution: Section of Haematology, Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Journal: Transfus Apher Sci. 2007 Aug;37(1):57-62. Epub 2007 Oct 4.
Abstract URL: Click here to view abstract

30. Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.

Author: Kharfan-Dabaja MA; Fahed R; Hussein M; Santos ES;
Institution: H. Lee Moffitt Cancer Center and Research Institute, Division of Blood and Marrow Transplantation, 12902 Magnolia Drive, BMT-WCB, Tampa, FL 33612, USA. Kharfama@moffitt.usf.edu
Journal: Expert Opin Investig Drugs. 2007 Nov;16(11):1799-815.
Abstract URL: Click here to view abstract

31. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.

Author: Boyiadzis M; Foon KA; Pavletic S;
Institution: University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Division of Hematology-Oncology, Department of Medicine, UPMC Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA. boyiadzism@upmc.edu
Journal: Expert Opin Biol Ther. 2007 Dec;7(12):1789-97.
Abstract URL: Click here to view abstract

32. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.

Author: Kretz-Rommel A; Bowdish KS;
Institution: Aracari Biotech, Del Mar, CA, USA. kretz-rommel@aracaribio.com
Journal: Expert Opin Biol Ther. 2008 Jan;8(1):5-15.
Abstract URL: Click here to view abstract

33. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept.

Author: Kharfan-Dabaja MA; Anasetti C; Santos ES;
Institution: Division of Blood and Marrow Transplantation, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute and University of South Florida, Tampa, FL 33612, USA. Kharfama@moffitt.usf.edu
Journal: Biol Blood Marrow Transplant. 2007 Apr;13(4):373-85.
Abstract URL: Click here to view abstract

34. Alemtuzumab in CLL and other lymphoid neoplasms.

Author: Ravandi F; O'brien S;
Institution: Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4095, USA. fravandi@mdanderson.org
Journal: Cancer Invest. 2006 Nov;24(7):718-25.
Abstract URL: Click here to view abstract

35. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?

Author: Nabhan C; Coutre S; Hillmen P;
Institution: Division of Hematology and Oncology, Lutheran General Hospital Cancer Center, Park Ridge, IL, USA. cnabhan@oncmed.net
Journal: Br J Haematol. 2007 Feb;136(3):379-92. Epub 2006 Nov 27.
Abstract URL: Click here to view abstract

36. Alemtuzumab in chronic lymphocytic leukemia.

Author: James DF; Kipps TJ;
Institution: University of California, San Diego, Division of Hematology & Oncology, UCSD Moores Cancer Center, Room #4311, 3855 Health Sciences Drive, La Jolla, CA 92093-0820, USA. dfjames@ucsd.edu
Journal: Future Oncol. 2007 Feb;3(1):29-42.
Abstract URL: Click here to view abstract

37. Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.

Author: Del Poeta G; Ilaria Del Principe M; Buccisano F; Maurillo L; Niscola P; Venditti A; Amadori S;
Institution: Cattedra di Ematologia, Universita Tor Vergata, Ospedale S.Eugenio, Via Fiume Giallo, 430 MA, 00144 Roma, Italy. g.delpoeta@tin.it
Journal: Expert Rev Anticancer Ther. 2006 Dec;6(12):1787-800.
Abstract URL: Click here to view abstract

38. Chronic lymphocytic leukemia.

Author: Chiorazzi, Nicholas; Rai, Kanti R; Ferrarini, Manlio;
Institution: Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY 11030, USA. nchizzi@nshs.edu
Journal: N Engl J Med 2005 Feb 24;352(8):804-15.